FGL1, fibrinogen-like protein 1, which is known as a novel potential immune checkpoint target [58], was recognized to be upregulated in tumor tissues and plasma specimens of ccRCC patients, and high FGL1 expression predicted a poor prognosis. This evidence concerns the gene FGL1 and neoplasm.